Edwards syndrome quad screen, edwards syndrome screening, Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Edwards Syndrome quad screen

Edwards' Syndrome quad screen

NIPT by Biomnis Offers Viable Alternative to Edwards' Syndrome Quad Screens??

Non-invasive prenatal testing (NIPT) is a form of genetic screening allowing for early detection of the most common fetal aneuploidies in at-risk pregnant women, including trisomy 13, 18, and 21. Although existing blood testing methods such as Edwards' Syndrome quad screensoffer effective screening for trisomy 18 and 21, they do not effectively detect Patau Syndrome (trisomy 13). Healthcare providers now have the option of prescribing women with heightened pregnancy risks non-invasive NIPT teststo accurately detect all three common trisomies. In many cases, these allow patients to avoid invasive sampling, leading to improved maternal and child health outcomes. They therefore offer a viable alternative to Edwards' Syndrome quad screens.

Trisomy 18 is a common chromosomal anomaly detected during fetal testing. The Edwards syndrome screening developed by EurofinsBiomnis uses cell-free DNA thanks to a sampling of maternal blood, and presents no risk to the fetus. Moreover, the test, which painstakingly analyses fetal DNA, has much greater sensitivity and specificity when compared to serum marker screening, yielding unusual accuracy. While the non-invasive prenatal genetic syndrome test is remarkably sensitive and specific, it is classified as an effective Edwards' Syndrome screening option for women at heightened risk of chromosomal defects. In the case of a positive result for one or more pathologies, an invasive procedure is administered to confirm the diagnosis.

For at-risk pregnancies, prescribing non-invasive Edwards' Syndrome tests offers reliable initial risk assessment for trisomy 18, as well as for Down Syndrome and Patau Syndrome. With detection rates exceeding 99%, the test is administered through a maternal blood sample by a primary healthcare provider or a Eurofins Biomnis partner laboratory. Available from 10 weeks of pregnancy, results for the cell-free fetal DNA test are available within 7 working days. Non-invasive Edwards' Syndrome tests may reduce unnecessary invasive sampling by up to 95%. Eurofins Biomnis follows the international recommendations of the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM).

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%